Abstract #1758

Liver proton density fat fraction as a trial endpoint in an international multi-site phase-II trial in patients with type 2 diabetes mellitus following treatment with duodenal mucosal resurfacing

Naomi S Sakai¹, Alan Bainbridge², David Maggs³, Margaret Hall-Craggs¹, Rachel Batterham^4,5, Stuart Taylor¹, and Manil Chouhan¹

¹UCL Centre for Medical Imaging, University College London, London, United Kingdom, ²Department of Medical Physics, University College London Hospitals, London, United Kingdom, ³Fractyl Laboratories Inc., Lexington, MA, United States, ⁴Centre for Obesity Research, University College London, London, United Kingdom, ⁵National Institute of Health Research, UCLH Biomedical Research Centre, London, United Kingdom

Vendor-certified proton density fat fraction (PDFF) sequences are commercially available across multiple scanner systems and represent a robust method for quantification of liver fat and liver T2* mapping. Type 2 diabetes mellitus (T2DM) is associated with non-alcoholic fatty liver disease and dysregulation of iron homeostasis. Duodenal mucosal resurfacing (DMR) is a novel treatment for patients with T2DM who have poor glycaemic control. We describe our technique for quality assurance across multiple sites using custom fat-water phantoms and report preliminary liver PDFF and liver iron concentration results from a cross-site, multi-vendor study in patients at baseline and 12 weeks after DMR.

This abstract and the presentation materials are available to members only; a login is required.

Join Here